{"slug":"livagen","seoKey":"livagen","displayName":"Livagen","codes":["KEDA"],"synonyms":["Lys-Glu-Asp-Ala","KEDA","KEDA tetrapeptide","H-Lys-Glu-Asp-Ala-OH","L-lysyl-L-glutamyl-L-aspartyl-L-alanine","lysyl-glutamyl-aspartylalanine (the NLM MeSH supplementary concept entry term)","Lyvagen (variant transliteration in PMID 15926314)","Ливаген (Russian spelling)"],"legalClass":"research_chemical","identifiers":{"cas":"433257-50-2","pubchemCid":87919683,"inchikey":"IKVDKWACACMDLR-BJDJZHNGSA-N","formula":"C18H31N5O9","molecularWeight":461.5,"sequence":"KEDA","wikidataQid":"Q137538072"},"approvals":[{"market":"US","status":"not_approved","date":"2026-09-15","note":"Not approved and not registered as a substance. Four federal queries returned nothing on 2026-09-15: no record in the substance registration system, which is why there is no substance code, no drug label, no adverse event report and no entry in the labelling database, whose state was 14 September 2026. The control query for an approved peptide returned five substance records, so the interface was working. The substance was also never nominated for the compounding bulks list, whose full text was read; the short peptide alanyl-L-glutamine stands in that list, so this is an absence and not an oversight. No warning letter naming this substance was found.","source":"https://gsrs.ncats.nih.gov"},{"market":"EU","status":"not_approved","date":"2026-09-15","note":"No centralised marketing authorisation, no assessment report and no withdrawal document. The register itself could not be queried on 2026-09-15 because the agency site answered an automated request with HTTP 403, so this is a negative finding drawn from the absence of any entry in every other authority database checked and from the absence of any registered trial. Recorded as an unverified gap rather than a nil result.","source":"https://www.ema.europa.eu/en/medicines"},{"market":"DE","status":"not_approved","date":"2026-09-15","note":"Neither a national nor an EU marketing authorisation exists, so an injectable preparation is not a marketable medicinal product and may not be imported or dispensed. The substance is also not named in the schedule to the Anti-Doping Act, whose full text was checked on 2026-09-15: section II lists peptide hormones, releasing factors and growth factors one by one, and no catch-all position covers a liver tetrapeptide. Possession is therefore not an offence under that provision, which changes nothing about the sporting ban. Unlike its sibling peptides there is no Russian capsule form either, so the novel-food question does not arise in practice.","source":"https://www.gesetze-im-internet.de/antidopg/anlage.html"},{"market":"UK","status":"not_approved","date":"2026-09-15","note":"No marketing authorisation known. The product register returned only the JavaScript shell of its search page on 2026-09-15, and the query and a control query with an approved active ingredient produced byte-identical answers of 122,696 characters each, so the negative finding could not be verified positively. It rests on the absence of any entry elsewhere and on the absence of any clinical development.","source":"https://products.mhra.gov.uk/"},{"market":"AU","status":"not_approved","date":"2026-09-15","note":"Not named in the Poisons Standard; the full text of the June 2026 instrument, signed 27 May 2026, was searched on 2026-09-15 for the trade name, the code and the sequence without a hit. There is no generic peptide position in that instrument, and short peptides are listed by name where they are scheduled, so this is a real absence. Absence of a listing is not a clearance: unapproved research peptides remain handled much as prescription substances are, and the registry itself was not programmatically queryable.","source":"https://www.legislation.gov.au/F2026L00633/asmade"},{"market":"CA","status":"not_approved","date":"2026-09-15","note":"No marketing authorisation and no entry in the drug product database; brand-name queries for the trade name and for the sequence returned empty results on 2026-09-15, while a control query for an authorised product returned its identification number, so the interface was working. The substance is nonetheless offered by research-chemical sellers with Canadian addresses.","source":"https://health-products.canada.ca/api/drug/drugproduct/?lang=en&type=json&brandname=livagen"},{"market":"CH","status":"not_approved","date":"2026-09-15","note":"No marketing authorisation known. The page for authorised medicines answered with HTTP 404 on 2026-09-15, so no direct register query was possible; this is a negative finding drawn from the absence of an authorisation in every market that could be checked and from the absence of any clinical development programme. Recorded as an unverified gap rather than a nil result.","source":"https://www.swissmedic.ch/"}],"devStage":"preclinical","strongestEvidence":"animal","wada":{"status":"prohibited","section":"S0","listYear":2026,"source":"https://www.wada-ama.org/en/prohibited-list"},"trials":[],"sameAs":["https://pubchem.ncbi.nlm.nih.gov/compound/87919683"],"lastVerified":"2026-09-15","version":"1.0","published":true,"locale":"en","title":"Livagen: what the studies show, status and safety","summary":"Livagen is a synthetic chain of four amino acids from a St Petersburg institute, sold as a liver peptide. No trial in people has ever been registered, and the liver findings behind that name sit in a patent that lapsed in 2022. Every published experiment comes from one research school. It is the one peptide of its series that never became a product anywhere.","updated":"2026-09-15","url":"https://mypep.app/peptides/livagen"}